Paper26258317
Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
Martin RC and 7 others. Ann Surg, 2015. Cited by 328 papers, by iCite.
Cite this record
ConductScience Library. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Papers, record 26258317. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26258317
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
- PubMed
Topics26
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Electroporation | Major topic |
| Pancreatic Neoplasms | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Case-Control Studies | |
| Catheter Ablation | |
| Chemoradiotherapy | |
| Combined Modality Therapy | |
| Disease-Free Survival | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Middle Aged | |
| Minimally Invasive Surgical Procedures | |
| Neoplasm Invasiveness | |
| Neoplasm Staging | |
| Patient Safety | |
| Registries | |
| Retrospective Studies | |
| Risk Assessment | |
| Survival Analysis | |
| Time Factors | |
| Treatment Outcome |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04276857 | Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer | Background | ClinicalTrials.gov | |
| NCT06231160 | Clinical Comparative Study of Systematic Therapy Combined With MWA and Systematic Therapy for Pancreatic Cancer | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 27257026 | Shock Therapy for Late-Stage Pancreatic Cancer Gets Closer Look. | https://conductscience.org/library/papers/27257026 |
Source PubMed
Cited by203
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 328 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42928513 | NCLX Inhibition plus Ca2+ Delivery Potentiates Electroporation and Antitumor Immunity in Pancreatic Ductal Adenocarcinoma. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42928513 | PubMed |
| 42872478 | Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results. | Oncologist | 2026 | https://conductscience.org/library/papers/42872478 | PubMed |
| 42779964 | Case Report: Late repeat pancreatic irreversible electroporation in the long-term multidisciplinary management of unresectable pancreatic ductal adenocarcinoma. | Front Oncol | 2026 | https://conductscience.org/library/papers/42779964 | PubMed |
| 42688057 | Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42688057 | PubMed |
| 42614700 | Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications. | Biomater Res | 2026 | https://conductscience.org/library/papers/42614700 | PubMed |
| 42445467 | Intraoperative irreversible electroporation for margin accentuation in locally advanced intrahepatic cholangiocarcinoma: a case series. | Front Surg | 2026 | https://conductscience.org/library/papers/42445467 | PubMed |
| 42397620 | Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/42397620 | PubMed |
| 42283922 | Revelations of pancreatic cancer treated by high-intensity focused ultrasound. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42283922 | PubMed |
| 42238591 | Anti-PD-1 blockade reverses low-intensity electric stimulation-driven pancreatic cancer progression. | Front Immunol | 2026 | https://conductscience.org/library/papers/42238591 | PubMed |
| 42146443 | The abscopal effect of IRE combined with anti-PD-1 achieves local ablation and systemic control of PDAC. | bioRxiv | 2026 | https://conductscience.org/library/papers/42146443 | PubMed |
| 42107701 | Production of Large Ellipsoidal Ablations Using Integrated Nanosecond Pulse Irreversible Electroporation Administered via a Single Applicator and Grounding Pad. | J Vasc Interv Radiol | 2026 | https://conductscience.org/library/papers/42107701 | PubMed |
| 41920765 | Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41920765 | PubMed |
| 41917374 | Interventional management of unresectable pancreatic cancer using transarterial chemoembolization and microwave ablation: a single-center evaluation over 12 years. | J Cancer Res Clin Oncol | 2026 | https://conductscience.org/library/papers/41917374 | PubMed |
| 41868439 | Impact of Voltage on the Production on Spherical Ablations for Integrated Time Nanosecond Pulse Irreversible Electroporation. | Bioelectricity | 2025 | https://conductscience.org/library/papers/41868439 | PubMed |
| 41803088 | Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/41803088 | PubMed |
| 41699145 | Expanded Indications and Role of Pancreatic Cyst/Mass Ablation. | Curr Gastroenterol Rep | 2026 | https://conductscience.org/library/papers/41699145 | PubMed |
| 41635510 | Novel Combination of Irreversible Electroporation and Allogenic Chimeric Antigen Receptor T-Cell Therapy Synergizes Therapeutic Outcomes in a Preclinical Human Pancreatic Cancer Mouse Model. | Research (Wash D C) | 2026 | https://conductscience.org/library/papers/41635510 | PubMed |
| 41592550 | Prospective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer. | Korean J Radiol | 2026 | https://conductscience.org/library/papers/41592550 | PubMed |
| 41178530 | Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine Models. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41178530 | PubMed |
| 41149494 | Use of Irreversible Electroporation in Pancreatic Cancer Patients: A Multi-Center Experience. | Curr Oncol | 2025 | https://conductscience.org/library/papers/41149494 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26258317
GET https://conductscience.org/api/papers/v1/26258317/cited_by?page=2